Dihexa FAQ: Comprehensive Questions & Answers

Dihexa is a synthetic compound developed to mimic hepatocyte growth factor (HGF) signalling. It activates the c-Met receptor on neurons, theoretically promoting synaptic plasticity, neuronal survival, and neuroprotection. Originally developed for Alzheimer's disease by Athira Pharma, it is now primarily of interest to the research and nootropic communities. See what is Dihexa for comprehensive background.

Dihexa activates the hepatocyte growth factor receptor (c-Met) on neuronal cell membranes. This triggers intracellular signalling cascades including PI3K/Akt and MAPK/ERK pathways, promoting neuronal survival, synaptic plasticity, and dendritic growth. In preclinical models, this signalling provides neuroprotection against excitotoxicity and amyloid-beta toxicity. For detailed mechanism information, see mechanism of action.

Dihexa is not a peptide despite being a growth factor mimetic. It's a small synthetic organic molecule (non-peptide). This distinction is important because non-peptide compounds can theoretically be taken orally (whereas peptides are typically degraded in the digestive system). Dihexa's small molecule nature is theoretically advantageous for absorption, though in practice oral bioavailability remains limited and uncertain in humans.

Dihexa and fosgonimeton are the same compound but different formulations. Dihexa is the basic molecule (typically in powder form or oral tablets). Fosgonimeton is an intravenous formulation specifically developed by Athira Pharma for clinical trials. The compound is identical; the delivery method differs. See fosgonimeton page for the clinical trial history.

Fosgonimeton is an intravenous formulation of Dihexa developed by Athira Pharma for clinical trials. It was designed to overcome oral bioavailability limitations. Phase 1 trials showed acceptable safety. However, ACT-AD Phase 2 and LIFT-AD Phase 2/3 trials both failed to demonstrate efficacy in Alzheimer's disease. Fosgonimeton development has been discontinued. See fosgonimeton for complete trial information.

Athira Pharma was the company developing fosgonimeton (intravenous Dihexa) for Alzheimer's disease. Following the LIFT-AD trial failure in September 2024, the company announced discontinuation of this program. Athira faced significant financial and strategic challenges from the failed trials and the retraction of a supportive publication.

A prominent study supporting Dihexa was retracted from Nature in 2023 due to concerns about experimental rigor and reproducibility. While retraction raised questions about the underlying science, independent confirmation studies exist (notably Sun et al., 2021 in transgenic Alzheimer's mice). The clinical trial failures (ACT-AD, LIFT-AD) provide the most definitive evidence regarding Dihexa's efficacy regardless of publication status.

Early marketing claims suggested Dihexa was millions of times more potent than nerve growth factor (NGF) at activating certain pathways in specific cell types. These claims were based on narrow in vitro comparisons under specific laboratory conditions and don't translate to real-world efficacy. The claim is not meaningfully applicable to in vivo effects in humans. Such dramatic comparative claims should be viewed with skepticism.

Dihexa has limited human safety data. Phase 1 trials in healthy volunteers showed acceptable short-term tolerability. However, long-term safety in humans is unknown. The primary concern involves c-Met activation and potential cancer risk, given c-Met's role as a proto-oncogene. Anyone considering use should consult a healthcare provider and understand these risks fully. See side effects page for detailed safety information.

c-Met is a proto-oncogene implicated in multiple cancer types including lung, liver, gastric, and other malignancies. Chronic c-Met activation can promote cell proliferation and tumorigenesis. Long-term Dihexa use theoretically increases cancer risk, though no human data quantify this risk. The risk is particularly concerning for individuals with cancer histories or family predisposition. This is the primary long-term safety concern for chronic use.

In Phase 1 trials, Dihexa was generally well-tolerated with minimal reported adverse events. However, human experience is extremely limited to short-term use. Self-experimenters occasionally report headache, nausea, sleep disruption, or mood effects. Long-term side effects are unknown. For comprehensive side effect information and contraindications, see detailed side effects documentation.

Dihexa's metabolism and CYP450 interactions are not well-characterized in humans. Whether it's metabolized by specific CYP450 enzymes (like CYP3A4, CYP2D6), and whether it inhibits or induces these enzymes, is unknown. This is a critical knowledge gap for anyone taking medications that depend on CYP450 metabolism. Potential drug interactions cannot be fully assessed. Medical consultation before combining Dihexa with other drugs is essential.

No human has taken Dihexa chronically for years. Long-term safety is unknown. The cancer risk concern intensifies substantially with longer duration of use. Most cautious approaches involve intermittent cycling (rather than continuous daily use) to theoretically minimize risk. Any long-term use decisions require medical oversight and realistic acknowledgment of unknown risks.

In preclinical studies, Dihexa was administered at concentrations that achieved specific brain levels. For oral use in humans, no established recommended dosage exists—no clinical trials in cognitively normal individuals have been conducted. Self-experimenters often use 5-20mg doses, but this is based on speculation rather than evidence. Optimal dosing for any indication remains unknown. See dosage page for more information.

Tablets circulating in research chemical markets are typically 10mg because this represents a convenient unit dose based on chemical solubility, bioavailability characteristics, and pill production constraints. The 10mg dose is not based on clinical evidence of efficacy—no clinical studies have established optimal dosing in humans. This is an arbitrary tablet size chosen by suppliers based on manufacturing convenience.

Oral bioavailability of Dihexa is limited and uncertain in humans. Preclinical studies used intravenous or intranasal administration routes. The intravenous formulation (fosgonimeton) was specifically developed because oral absorption is poor and insufficient to achieve therapeutic brain levels. Whether oral dosing in humans achieves therapeutically relevant brain concentrations remains unknown. This is a major limitation for self-experimental use.

No human data exist on onset time. Theoretically, as a neuroprotective compound working through gradual synaptic plasticity changes, it would require weeks to months to produce effects (unlike stimulants acting acutely within hours). This timeline is entirely speculative. Individual variability in pharmacokinetics and biological response would be substantial.

No established cycling protocol exists based on clinical evidence. Some self-experimenters cycle based on theoretical principles (e.g., 5 days on, 2 days off; or 3 weeks on, 1 week off) to potentially prevent tolerance development or c-Met receptor downregulation. However, no human data support any particular cycling pattern. Tolerance development in humans is unknown. Cycling decisions should be made with medical guidance.

Dihexa powder should be stored in cool, dry conditions away from direct light. Room temperature (around 20°C) in a sealed, airtight container is generally recommended. Avoid humid environments that promote degradation and chemical changes. If purchased from research chemical suppliers, storage guidance should be provided with documentation. Proper storage maintains chemical stability and safety over time.

Dihexa is not approved as a medicine or food supplement in the UK. Its legal status is ambiguous—it does not appear to be explicitly scheduled as a controlled substance under UK law, but it is not legally marketed for human consumption. Possession for personal use may not be illegal, but supply, distribution, and commercial activity face legal uncertainties. See legal status page for full details.

Dihexa is not legally marketed in the UK through mainstream pharmaceutical or supplement channels. Some research chemical suppliers may offer it, but purchasing from such sources carries both legal and safety risks. Quality control is not guaranteed, and suppliers may not consistently provide certificates of analysis (COA). We recommend consulting with a healthcare provider about safer, legal alternatives.

A Certificate of Analysis (COA) is documentation from an independent testing laboratory confirming the identity, purity, and safety of a compound. When purchasing Dihexa from research chemical suppliers, a COA is essential for verifying you're receiving what was advertised and at appropriate purity levels. Without a COA, you cannot verify product quality, safety, or contaminant levels. Always request and review a COA from suppliers before purchasing.

Dihexa showed promise in preclinical models and early human trials, but failed in late-stage clinical trials. The LIFT-AD phase 2/3 trial, completed September 2024, demonstrated no cognitive benefit compared to placebo. The intravenous formulation (fosgonimeton) did not slow cognitive decline in Alzheimer's patients. Athira Pharma has discontinued Dihexa/fosgonimeton development for Alzheimer's indication. See Alzheimer's research page for complete information.

No clinical evidence demonstrates cognitive benefits in healthy humans. Preclinical studies tested cognitively impaired or aged animals, not healthy ones. The failed Alzheimer's trials (where neuroprotective benefit was most needed and plausible) suggest that even well-designed compounds with sound mechanisms may not translate to human efficacy. Any cognitive benefit in healthy individuals remains entirely theoretical and unproven.

Stacking combinations (Dihexa + Semax, Dihexa + modafinil, Dihexa + cholinergics) circulate in the nootropic community, but no clinical data support any combination strategy. Pharmacokinetic and pharmacodynamic interactions are inadequately characterized. Combining multiple compounds increases unpredictability and risk substantially. Any stacking should involve careful medical consultation, monitoring, and realistic risk acknowledgment. See cognitive enhancement page for stack protocols discussed in communities.

Dihexa does not appear on current WADA (World Anti-Doping Agency) banned substances lists. However, as a growth factor receptor mimetic, it could potentially be classified as a banned substance under certain categories in future. Elite athletes should verify current WADA status before use, as regulations evolve. For amateur athletes, ergogenic use of non-approved research compounds raises both regulatory and ethical concerns.

In preclinical studies, Dihexa crosses the blood-brain barrier and achieves central nervous system concentrations. However, the efficiency of crossing and actual brain penetration at oral doses in humans remains uncertain and uncharacterized. This uncertainty is why fosgonimeton (intravenous formulation) was developed—to ensure reliable brain delivery. The bioavailability and brain penetration of oral Dihexa in humans is unknown.